© Springer-Verlag Berlin Heidelberg 2015Nima Rezaei (ed.)Cancer Immunology10.1007/978-3-662-44946-2_26 26. Psychoneuroendocrinoimmunotherapy of Cancer Paolo Lissoni1 , Giusy Messina1 and Franco Rovelli1 (1) Italian Association of Integrative Medicine (AIMI), Milan, 21124, Italy Paolo Lissoni (Corresponding author) Email: p.lissoni@hsgerardo.org Giusy Messina…
Fig. 24.1 This is a proposed schema for intensive immune monitoring. Flow cytometry can be performed on peripheral blood to analyze multiple parameters for T cell activation/exhaustion markers, regulatory T…
Fig. 20.1 Two mechanisms proposed to explain the association between TAMs and tumorigenesis. (a) A large set of chemokines (CCL2 and others) and cytokines (G-CSF and so on) secreted by…
22. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711.PubMed 23. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al. Rapid…
© Springer-Verlag Berlin Heidelberg 2015Nima Rezaei (ed.)Cancer Immunology10.1007/978-3-662-44946-2_18 18. Recent Advances in the Use of NK Cells Against Cancer Amy E. Gillgrass1 , Tamara Krneta1 and Ali A. Ashkar1 (1) Department of Pathology and Molecular Medicine, McMaster Immunology Research Center…
Gammaretrovirus vectors Lentivirus vectors Adenovirus vectors Adeno-associated virus vectors Herpes simplex virus-1 vectors Cloning capacity 7–7.5 kb 18 kb 37 Kb 4.9 kb Up to 152 kb (dependent on…
Primary concerns in the clinical utilization of CAR-modified T cells I. T lymphocyte population selection and culture (a) Mechanism of T cell activation (OKT3, CD3-CD28 beads) (b) Cytokines or small…
Cytokine Condition Chemotherapy Phase State Reference Outcome IL-2 Melanoma Dacarbazine II Ongoing NCT00553618 Melanoma +Cy II Ongoing NCT01833767 Breast cancer +Paclitaxel II Ongoing NCT01134250 Breast cancer +Doxorubicin II Ongoing NCT01131364 …
Bone marrow Peripheral blood Cord blood Limiting factor HLA match HLA match Cell quantity Minimal HLA match 4/6 9/10 9/10 GVHD risk Yes Yes No Biggest risk GVHD GVHD…
Tumor type Markers Reference Bladder ABCG2high SP (side population, Hoechst dye) [12] ALDH1high [13] Breast CD44+CD24−/low [10] ALDH1high [14] Colon CD133+ [15] EpCAMhigh CD44+ [16] ALDH1high [17] Gastric CD44+ [18]…
